It is very uncertain whether pentoxifylline with antibiotics (any dose or duration) changes all‐cause mortality during hospital stay compared with immunoglobulin M‐enriched intravenous immunoglobulin with antibiotics (very low certainty).
It is very uncertain whether pentoxifylline with antibiotics (any dose or duration) changes all‐cause mortality during hospital stay compared with pentoxifylline with antibiotics and immunoglobulin M‐enriched… (very low certainty).
Pentoxifylline with antibiotics (any dose or duration) may leads to lower all‐cause mortality during hospital stay compared with placebo or no intervention (low certainty).
It is very uncertain whether cefazolin plus amikacin changes all‐cause mortality maximum compared with vancomycin plus amikacin (very low certainty).
It is very uncertain whether vancomycin plus gentamicin changes all‐cause mortality maximum compared with vancomycin plus aztreonam (very low certainty).
It is very uncertain whether ticarcillin plus clavulanic acid changes all‐cause mortality maximum compared with flucloxacillin and gentamicin (very low certainty).
It is very uncertain whether cloxacillin plus amikacin changes all‐cause mortality maximum compared with cefotaxime plus gentamicin (very low certainty).
It is very uncertain whether meropenem changes all‐cause mortality maximum compared with standard care (very low certainty).
It is very uncertain whether ampicillin plus gentamicin changes all‐cause mortality maximum compared with penicillin plus gentamicin (very low certainty).
It is very uncertain whether piperacillin changes all‐cause mortality maximum compared with ampicillin plus amikacin (very low certainty).
It is very uncertain whether piperacillin plus tazobactam changes all‐cause mortality maximum compared with amikacin (very low certainty).
It is very uncertain whether ticarcillin plus clavulanic acid changes all‐cause mortality maximum compared with piperacillin plus gentamicin (very low certainty).